MeSH D015658 - hiv infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D015229:Viral sexually transmitted diseases
0 Companies
0 Drugs
Success rate
D000086982:Blood-borne infections
0 Companies
0 Drugs
Success rate
D007153:Immunologic deficiency syndromes
D016180:Lentivirus infections
0 Companies
0 Drugs
Success rate
D015658:Â
Hiv infections
D000071297:Acute retroviral syndrome
0 Companies
0 Drugs
Success rate
D000163:Acquired immunodeficiency syndrome
D000386:Aids-related complex
0 Companies
0 Drugs
Success rate
D006679:Hiv seropositivity
0 Companies
0 Drugs
Success rate
D015526:Aids dementia complex
0 Companies
0 Drugs
Success rate
D016263:Aids-associated nephropathy
0 Companies
0 Drugs
Success rate
D019053:Hiv enteropathy
0 Companies
0 Drugs
Success rate
D019247:Hiv wasting syndrome
0 Companies
0 Drugs
Success rate
D020943:Central nervous system aids arteritis
0 Companies
0 Drugs
Success rate
D017088:Aids-related opportunistic infections
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AbbVie | Lopinavir, Ritonavir | Kaletra |  | 2001-03-19 | $291 M | Q2/19-Q1/20 |
| Ritonavir | Norvir |  | 1996-08-25 | $165 M | Q1/12-Q1/13 | |
| Alvogen | Nevirapine | Nevirapine |  | 2015-07-10 |  |  |
| American Regent | Zidovudine | Zidovudine |  | 2010-05-06 |  |  |
| Amneal Pharmaceuticals | Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2018-08-22 |  |  |
| Etravirine | Etravirine |  | 2021-06-14 |  |  | |
| ANDA Repository | Lamivudine, Zidovudine | Lamivudine Zidovudine |  | 2018-04-10 |  |  |
| Annora Pharma | Lamivudine | Lamivudine |  | 2019-03-21 |  |  |
| Apotex | Abacavir | Abacavir |  | 2012-12-17 |  |  |
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2021-06-16 |  |  | |
| Lamivudine | Lamivudine |  | 2011-12-02 |  |  | |
| Nevirapine | Nevirapine |  | 2012-05-22 |  |  | |
| Aurobindo Pharma | Abacavir | Abacavir |  | 2012-12-17 |  |  |
| Lamivudine, Abacavir | Abacavir Lamivudine |  | 2018-11-15 |  |  | |
| Didanosine | Didanosine |  | 2012-08-14 |  |  | |
| Efavirenz | Efavirenz |  | 2018-09-21 |  |  | |
| Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz, Emtricitabine, Tenofovir Disoproxil |  | 2018-09-04 |  |  | |
| Tenofovir disoproxil, Efavirenz, Lamivudine | Efavirenz, Lamivudine Tenofovir Disoproxil |  | 2018-08-15 |  |  | |
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2018-01-26 |  |  | |
| Lamivudine | Lamivudine |  | 2016-11-21 |  |  | |
| Tenofovir disoproxil, Lamivudine | Lamivudine Tenofovir Disoproxil |  | 2018-05-15 |  |  | |
| Lamivudine, Zidovudine | Lamivudine Zidovudine |  | 2017-05-05 |  |  | |
| Nevirapine | Nevirapine |  | 2012-05-22 |  |  | |
| Stavudine | Stavudine |  | 2008-12-29 |  |  | |
| Zidovudine | Zidovudine |  | 2005-09-19 |  |  | |
| Emtricitabine | Emtricitabine |  | 2023-03-15 |  |  | |
| Barr Pharmaceuticals | Didanosine | Didanosine |  | 2004-12-03 |  |  |
| Boehringer Ingelheim | Tipranavir | Aptivus |  | 2005-10-25 |  |  |
| Nevirapine | Viramune |  | 1996-06-21 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
76%187/245
Phase 2
57%173/302
Phase 3
53%143/272
Approved: 58Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use